OSTEOCERIN TABLETS

Indications

• Symptomatic relief of mild to moderate osteoarthritis of the knee

Dosage

Children: Refer to the BNF for Children for

Adults: 200–400 mg daily, maximum 6.5 mg/kg per day, or 1250 mg once daily, or 1500 mg once daily dissolved in at least 250 mL of water; review treatment if no benefit after 2–3 months.

Mechanism of action

The mechanism of action of glucosamine in joint health is not entirely clear, but it is believed to involve several pathways. Glucosamine is a precursor for glycosaminoglycans, which are essential for cartilage integrity. It may also reduce inflammation by inhibiting interferon gamma and Nuclear factor kappa B subunit 65 (NF-κB p65), which could improve symptoms of arthritis and joint pain. Upon uptake by living cells, glucosamine reacts with ATP to form glucosamine-6-phosphate, further contributing to glycosaminoglycan synthesis.

Pharmacodynamics

Glucosamine is theorized to provide essential building blocks for the synthesis of glycosaminoglycans, potentially slowing the progression of osteoarthritis and alleviating joint pain. Although some studies have indicated modest improvements in joint pain and function among users, the overall evidence remains inconclusive. Glycosaminoglycans are critical for maintaining cartilage elasticity, strength, and flexibility, which are vital for joint health.

Pharmacokinetics

After oral administration, glucosamine is absorbed in the gastrointestinal tract and transported into the bloodstream, where it is metabolized into various forms, including glucosamine-6-phosphate. The exact pharmacokinetics, such as absorption rate and half-life, remain largely undefined, and much of the data is derived from animal studies. Further research is required to clarify its pharmacokinetic profiles in humans.

Adverse effects

• Constipation
• Diarrhoea
• Fatigue
• Gastrointestinal discomfort
• Headache
• Nausea
• Flushing
• Skin reactions

Interactions

• Glucosamine + warfarin: Severe (increases anticoagulant effect)
• Glucosamine + coumarins: Severe (increases anticoagulant effect)
• Glucosamine + acenocoumarol: Unknown (decreases anticoagulant effect)
• Glucosamine + coumarins: Unknown (decreases anticoagulant effect)

Precautions

• Asthma
• Impaired glucose tolerance
• Predisposition to cardiovascular disease

Pregnancy

Safety during pregnancy has not been established; consult with a healthcare provider.

Breast-feeding

Safety during breastfeeding has not been established; consult with a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Alateris®
• Dolenio®
• Glusartel®

Indications

• Osteoarthritis
• Chronic pain conditions
• Musculoskeletal disorders

Dosage

Children: Refer to the appropriate clinical guidelines for pediatric dosing information.

Adults: Refer to the appropriate clinical guidelines for specific dosing information.

Mechanism of action

Methanediacerein acts as a slow-acting anti-rheumatic drug. It inhibits the production of interleukin-1 (IL-1), a cytokine that plays a key role in inflammatory processes, particularly in osteoarthritis. By reducing IL-1 levels, methanediacerein helps to decrease inflammation and promote cartilage synthesis, thereby supporting joint health and function.

Pharmacodynamics

The pharmacodynamic effects of methanediacerein include anti-inflammatory and analgesic properties, which contribute to pain relief and improved mobility in patients with osteoarthritis. Its ability to inhibit cytokine production is crucial in mitigating the inflammatory response that leads to joint pain and degeneration.

Pharmacokinetics

Methanediacerein is well-absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The drug undergoes hepatic metabolism, with significant first-pass metabolism leading to the formation of active metabolites. The elimination half-life is approximately 8 to 12 hours, and it is primarily excreted through the urine. Renal impairment may affect the clearance of the drug and its metabolites.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Dizziness
• Headache
• Rash

Precautions

• Use with caution in patients with gastrointestinal disorders.
• Monitor for allergic reactions in patients with known sensitivities.

Pregnancy

The safety of methanediacerein in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether methanediacerein is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablet
• Topical cream

Indications

• Type 2 diabetes mellitus
• Hyperglycemia management

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations for pediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on individual patient needs and the specific sulfonylurea being used.

Mechanism of action

Sulfonylureas, including sulfonyl, act by binding to the sulfonylurea receptor (SUR) on pancreatic beta cells. This interaction closes ATP-sensitive potassium channels, leading to depolarization of the cell membrane. As a result, calcium channels open, causing an influx of calcium ions that trigger insulin secretion. Additionally, sulfonylureas may also enhance the binding of insulin to its receptors in peripheral tissues, thus improving insulin sensitivity.

Pharmacodynamics

The pharmacodynamic effects of sulfonylureas include increased insulin secretion from the pancreas and improved peripheral utilization of glucose. They also exhibit a duration of action that can vary depending on the specific sulfonylurea used, with some having a longer duration than others. The overall effect leads to a decrease in blood glucose levels, which is essential for managing hyperglycemia in diabetic patients.

Pharmacokinetics

Sulfonylureas are generally well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. They are highly protein-bound, mainly to albumin, and have variable half-lives depending on the specific drug. Metabolism primarily occurs in the liver, and the metabolites are excreted via the kidneys, necessitating caution in patients with renal impairment.

Interactions

• bosentan+sulfonylureas: Severe (increases risk of hepatotoxicity)
• amiodarone+sulfonylureas: Moderate (increases exposure)
• voriconazole+sulfonylureas: Moderate (increases concentration)
• ceritinib+sulfonylureas: Moderate (increases exposure)
• metreleptin+sulfonylureas: Moderate (increases risk of hypoglycaemia)
• roxadustat+sulfonylureas: Moderate (increases exposure)
• darolutamide+sulfonylureas: Unknown (increases concentration)
• bulevirtide+sulfonylureas: Unknown (increases exposure)
• ceftobiprole+sulfonylureas: Unknown (increases concentration)
• chloramphenicol+sulfonylureas: Unknown (increases exposure)

Pregnancy

Sulfonylureas may be used with caution in pregnancy. However, they should only be prescribed if the potential benefit outweighs the risk. Glycemic control is essential during pregnancy.

Breast-feeding

Sulfonylureas are generally not recommended during breastfeeding due to the potential risk of hypoglycaemia in the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on the condition being treated. Dosing may vary based on individual patient needs and response.

Mechanism of action

Methylphenidate primarily acts as a dopamine and norepinephrine reuptake inhibitor. By blocking the reuptake of these neurotransmitters, it increases their availability in the synaptic cleft, enhancing neurotransmission and stimulating brain activity associated with attention and impulse control.

Pharmacodynamics

The drug has a quick onset of action, typically within 30 to 60 minutes after administration, with effects lasting for several hours. Its stimulant properties lead to increased alertness, improved concentration, and decreased impulsivity in patients with ADHD. The therapeutic effects are thought to be related to its action on the prefrontal cortex, which is involved in executive functions.

Pharmacokinetics

Methylphenidate is well absorbed after oral administration and reaches peak plasma concentrations within 1 to 2 hours. It is extensively metabolized in the liver, primarily by the carboxylesterase CES1A1 enzyme, to its active metabolite, ritalinic acid. The elimination half-life is approximately 2 to 4 hours, and it is excreted mainly through urine, with less than 1% of the dose excreted unchanged.

Pregnancy

The safety of uspmethyl in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether uspmethyl is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Mechanism of action

The mechanism of action of glucosamine in joint health is unclear, however there are several possible mechanisms that contribute to its therapeutic effects. Because glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, glucosamine supplements may help to rebuild cartilage and treat the symptoms of arthritis. Some in vitro studies show evidence that glucosamine reduces inflammation via inhibition of interferon gamma and Nuclear factor kappa B subunit 65 (NF-κB p65), improving the symptoms of arthritis and joint pain. Clinical relevance is unknown at this time. When taken up by living cells, glucosamine reacts with ATP to form glucosamine-6-phosphate, the natural precursor of glycosaminoglycans (GAGs) that contain N-acetylglucosamine (keratan sulfate and Hyaluronan) and those that have N-acetylgalactosamine (heparan sulfate and chondroitin sulfate). These GAGs are polysaccharides composed of hexosamines and monosaccharides (e.g., galactose and glucuronic acid) arranged as a linear chain of repeating disaccharide units (such as the glucuronic acid and N-acetylgalactosamine-6-sulfate of chondroitin sulfate). With the exception of hyaluronan, GAGs do not exist alone in nature but are attached to specific "core" proteins, and the composite structures are called proteoglycans (protein-glycosaminoglycans). Both hyaluronan and many different kinds of proteoglycans (such as aggrecan, versican, and syndecan) are abundant throughout the body where they perform diverse functions.

Pharmacodynamics

The administration of glucosamine, in theory, provides a building block towards the synthesis of glycosaminoglycans, slowing the progression of osteoarthritis and relieving symptoms of joint pain. Studies to this date examining the efficacy of glucosamine sulfate have been inconclusive. Glycosaminoglycans contribute to joint cartilage elasticity, strength, and flexibility. A systematic review of various studies and guidelines determined that modest improvements were reported for joint pain and function in patients taking glucosamine. A consistent joint space narrowing was observed, but with an unclear clinical significance.